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ABSTRACT
 
Objectives: 
 
This study was designed to evaluate the
effects of an employee inﬂuenza vaccination campaign,
measured in terms of health and economic beneﬁts.
Methods: Colombian bank employees volunteered to
take part in this prospective observational study involving
two groups: vaccinated and nonvaccinated. Socioeco-
nomic and health status information, including inﬂuenza-
like symptoms, sick leave, and postvaccination adverse
events, were collected via questionnaires. Cost–beneﬁt
analyses were performed to determine whether the
employer would save money overall by paying for the
vaccination program.
Results: Between October 2000 and May 2001, 424
vaccinated subjects and 335 nonvaccinated subjects
volunteered to join the study. Cumulative incidence of
inﬂuenza-like illness (ILI) was lower among vaccinated
(14.6%) than nonvaccinated subjects (39.4%). Fever
was the most common ILI symptom (93% of all
reported ILI). Absence rates because of ILI were simi-
lar in the two groups (2.59%-2.69%). Assuming
that employees with ILI who continue to work have
reduced effectiveness (30%-70% of normal) the
employer can save US$6.4 to US$25.8 per vaccinated
employee based on labor costs alone. This saving
increases to US$89.3 to US$237.8 when operating
income is also considered. Sensitivity analyses indicate
that the vaccination program will be cost saving for
vaccination coverage above 20% and ILI rates above
10%.
Conclusions: Among the studied volunteers, ILI has sig-
niﬁcant impact on work productivity in terms of indirect
costs. Implementing an inﬂuenza vaccination program
would reduce the burden of ILI and save substantial
amounts of money for the company.
Keywords: cost–beneﬁt, inﬂuenza, occupational health,
vaccination.
 
Introduction
 
Inﬂuenza is an acute, febrile illness that primarily
affects the respiratory tract. The disease is charac-
terized by fever (38–40
 
∞
 
C), headaches, myalgia,
sore throat, and inﬂammation [1]. It is a seasonal
disease, affecting northern, temperate zones during
winter and the tropics during the rainy season [1].
Inﬂuenza is commonly misconceived to be an
inconvenient infection rather than a potentially
lethal hazard. Nevertheless, the elderly and patients
with underlying chronic medical conditions such as
chronic pulmonary or cardiovascular disorders,
metabolic disorders, hemoglobinopathies, or immu-
nosuppression are at risk of inﬂuenza with a high
risk of potential complications including heart fail-
ure, pneumonia, respiratory insufﬁciency, and even
death. An estimated 20,000 to 50,000 people died
perepidemic year as a result of inﬂuenza in the
United States according to surveys performed from
1972 to 1973 through 1980 to 1981 [2].
The potential beneﬁts of vaccination against
inﬂuenza have been documented extensively since
the 1940s [1]. The Advisory Committee on Immu-
nization Practices (ACIP) recommends vaccination
against inﬂuenza in numerous countries worldwide
[3].
Inﬂuenza causes a dramatic increase in work
absenteeism and disease burden among otherwise
healthy adults during peak levels of inﬂuenza and
inﬂuenza-infected individuals who attend work are
often less productive than normal [4–9]. For exam-
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ple, in the United States, between 1971 and 1978,
approximately US$764 million per year was lost
because of absenteeism resulting from inﬂuenza epi-
demics [6]. These losses are not caused by severe
illness in people from high-risk groups, but by
uncomplicated illness in otherwise healthy, produc-
tive adults. Almost half of reported losses resulted
from illness in workers aged 25 to 44 years [6,10].
Annual inﬂuenza vaccination campaigns for the
workforce at the start of an inﬂuenza season might
reduce the ﬁnancial losses that result from inﬂu-
enza, but the campaigns themselves have costs that
need to be met. For example, an employer imple-
menting such a campaign would need to purchase
the vaccine, employ health-care staff to run the
campaign, and then accept lost productivity while
the  workforce  was  being  vaccinated  and  during
any subsequent absence caused by vaccine-related
adverse events. Thus, the economic costs of uncon-
trolled inﬂuenza in the workforce must be com-
pared with the costs of implementing inﬂuenza
vaccination programs.
Several studies of the costs and beneﬁts of annual
inﬂuenza vaccination programs have demonstrated
their economic beneﬁts to proﬁt-driven companies.
A recent review of 11 health economic studies
between 1979 and 2000 revealed that eight showed
clear beneﬁts of vaccinating the workforce [11].
Failure to show any beneﬁt was linked to high vac-
cination costs, low levels of inﬂuenza, or short dura-
tion of sick leave. In reviewed studies where cost
beneﬁts were found they mostly resulted from indi-
rect cost savings (CS) such as losses arising from
absenteeism or low levels of production while at
work [11]. In fact, such indirect costs are the most
important considerations for the beneﬁts of such
vaccination programs [11,12]. Other health eco-
nomic analyses have shown beneﬁts of vaccination
programs where inﬂuenza rates among the work-
force are as low as 2% and that vaccination of the
healthy working population aged 18 to 50 years
against inﬂuenza in a variety of settings is cost-
effective during most inﬂuenza seasons [13,14].
These ﬁndings have been conﬁrmed in randomized,
double blind, and placebo-controlled trials of inﬂu-
enza vaccination of healthy working adults [4,11].
Vaccination against inﬂuenza has also been shown
to reduce absenteeism signiﬁcantly [15]. The Amer-
ican Center for Disease Control and Prevention
(CDC) has shown that the beneﬁts of vaccination of
healthy people less than 65 years old are optimized
if a vaccine strain is chosen that matches the strain
responsible for disease outbreaks in that year [3].
Elsewhere, health economic modeling has been used
to indicate the pricing of a novel, nasal delivery sys-
tem for an inﬂuenza vaccine, to enable programs
using this system to break even ﬁnancially [16].
The majority of these published studies have
measured the effects of vaccination in northern,
temperate climates. Few studies have been imple-
mented in tropical countries such as Colombia
where inﬂuenza circulation is perceived to be mod-
erate. It is important to evaluate the potential health
and economic beneﬁts of vaccination against inﬂu-
enza in these countries.
The study described here evaluates the economic
impact of an inﬂuenza vaccination program in a
Colombian banking company. The primary objec-
tive of this study was to determine whether vacci-
nation against inﬂuenza decreases the rate of
inﬂuenza-like illness (ILI) and levels of absenteeism
and how vaccination affects the ﬁnancial losses
associated with ILI in healthy adults in an occupa-
tional setting. The secondary objective was to deter-
mine whether the indirect ﬁnancial beneﬁts of the
vaccination program outweigh the overall costs.
 
Methods
 
This nonrandomized, prospective, and observa-
tional study was conducted among the workforce of
a bank in Bogota, Colombia between October 2000
and May 2001. The study was designed to evaluate
the economic beneﬁts of vaccination from the point
of view of the employer exclusively.
The bank’s entire workforce (
 
N
 
 
 
=
 
 2598) was
asked to participate in the study via the company’s
internal information services—Internet, fax, notice
boards, and newspapers. To be eligible, employees
had to be in full-time employment, aged 18 to 64,
not be at high risk of complications as a result of
inﬂuenza, not to have been diagnosed with inﬂu-
enza in the previous 3 months nor already vacci-
nated against inﬂuenza during winter 2000. A total
of 834 employees were eligible and willing to par-
ticipate to the study. Questionnaires were com-
pleted by 827 but 68 had to be excluded, resulting
in a ﬁnal sample size of 759.
Completed questionnaires provided demo-
graphic data, medical history, and employment-
speciﬁc data, including the number of people,
including children, living in each household and the
employee’s education, level of responsibility within
the workplace, and any underlying chronic medical
conditions considered to be at-risk factors for inﬂu-
enza. Preliminary data were collected at the
appointment during which vaccine was adminis-
tered (vaccinated group) or by mail (nonvaccinated
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group). These data included an analysis of the
employees’ own perception of their health status,
obtained using an analog scale, 0 to 10, where 0 is
worst possible health and 10 is normal. Subjects
estimated their ability to perform their usual activ-
ities using a similar scale, with 0 corresponding to
an inability to perform their usual activities and 10
corresponding to an unhindered ability to perform
usual activities.
An annual vaccination program was estab-
lished with vaccination occurring during the ﬁrst
week of October: vaccinated subjects received one
dose of an inactivated, split inﬂuenza vaccine
(IMOVAX®, Aventis Pasteur, Lyon, France) as an
intramuscular injection in the leg or upper arm.
The program was organized and implemented
internally, involving occupational nurses employed
in the occupational health department. Thus, the
timeframe of intervention was 1 week whereas the
analytical horizon—follow-up and measurement
of vaccination’s costs and beneﬁts—was from
October to May.
The vaccinated group reported any adverse
events within 7 days postvaccination, including
associated treatments or sick leave. During the
entire study period—8 months—all subjects com-
pleted monthly questionnaires administered by tel-
ephone. Occurrence of ILI was noted, deﬁned as the
occurrence of a febrile illness of at least 2 days’
duration having at least one systemic symptom—
fever, chills, and myalgia—and at least one respira-
tory-tract symptom—rhinorrhoea, sore throat,
cough, and hoarseness. Adverse events—fever,
tiredness, muscle aches, headache, and allergic reac-
tion; and pain, redness, itchiness, and swelling at
the vaccination site—were recorded during the
7 days after vaccination.
 
Health economic analysis and statistics. 
 
The perc-
entage (%) effectiveness of vaccination was calcu-
lated using the equation:
% effectiveness 
 
=
 
 [(%ILI in nonvaccinated group) 
 
-
 
 (% ILI in vaccinated group)]/(% ILI in the 
nonvaccinated group).
Qualitative and quantitative data from the two
groups were compared using analysis of variance
(
 
ANOVA
 
) or nonparametric tests (Mann–Whitney
Wilcoxon for the comparison of two data sets or
Kruskal–Wallis for comparison of more than two
data sets) if 
 
ANOVA
 
 conditions could not be applied.
Qualitative variables were compared using chi-
square tests or Fisher exact tests if conditions for
chi-square tests could not be respected. Cochran–
Mantel–Haenszel tests were used for comparisons
with adjustments for deﬁned factors. Association
between two quantitative variables was estimated
by using the Pearson linear correlation coefﬁcient or
Spearman when Pearson’s condition could not be
applied.
The cost–beneﬁt evaluation of the vaccination
program was performed from the perspective of the
employer, focusing on the direct vaccination pro-
gram costs including the costs of vaccines, materi-
als, and cost of administration, indirect costs of the
vaccination program including the cost of time for
the employees to get the vaccine and the indirect
cost of adverse events in terms of productivity, indi-
rect costs of ILI including sick leave, either with or
without temporary replacement of the employee,
and the cost of productivity lost in case of employ-
ees working while sick (Table 1). The ﬁnancial costs
of these outcomes to the employer were estimated
by considering salaries as well as the loss of income
caused by the employee’s absence or illness. Both
 
Table 1
 
Sources and calculations for economic evaluation data
 
Economic evaluation items Economic calculation (including operating income)
Direct vaccination program costs
Costs of  vaccines and materials Purchasing prices
Costs of  administration of  vaccines by occupational health nurse Time 
 
¥ 
 
hourly labor costs
Indirect vaccination program costs
Cost of  average time lost by vaccinated employees during
administration
Time (20 min) 
 
¥ 
 
(hourly labor costs 
 
+
 
 individual hourly operating income)
Cost of  working days lost due to adverse events Time 
 
¥ 
 
(daily labor costs 
 
+
 
 daily individual operating income)
Indirect ILI costs
Cost of  sick leaves due to ILI when the employees are not
replaced
Number of  days 
 
¥ 
 
(daily labor costs 
 
+
 
 daily individual operating income)
Cost of  decreased productivity due to ILI episodes Number of  days 
 
¥ 
 
% of  reduced effectiveness 
 
¥ 
 
(daily labor costs 
 
+
 
 daily 
individual operating income)
Indirect vaccination program beneﬁts (not vaccinated vs. vaccinated)
Avoided cost of  sick leaves due to ILI when the employees are 
not replaced
Number of  days 
 
¥ 
 
(daily labor costs 
 
+
 
 daily individual operating income)
Avoided cost of  decreased productivity due to ILI episodes Number of  days 
 
¥ 
 
% of  reduced effectiveness 
 
¥ 
 
(daily labor costs 
 
+
 
 daily 
individual operating income)
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the employer and contracted Health Maintenance
Organizations (HMOs) are responsible for meeting
the labor costs for absent employees. In this case,
the employer pays 100% of the costs for the ﬁrst
3 days of absence and for each subsequent day the
company pays 33% and the contracted HMO pays
67% of the costs. Nevertheless, the employer ulti-
mately bears these costs through the annual con-
tract with the HMO, so full salary costs were
included in these calculations.
Two scenarios have been considered:
• The base case that includes salaries plus operat-
ing income (OI); and
• The low case scenario that considers salaries
alone.
The net ﬁnancial beneﬁt of the vaccination pro-
gram, in the form of the CS was calculated using
formula:
CS 
 
=
 
 (cost of ILI in nonvaccinated employees) 
 
-
 
(cost of ILI in vaccinated employees 
 
+
 
 cost of 
vaccination program)
The net beneﬁt per vaccinated employee is calcu-
lated by dividing the overall net beneﬁt by the
number of vaccinated employees.
Employees with ILI who attend work are likely
to be less efﬁcient. Cost–beneﬁt analyses were per-
formed taking into account three levels of such
reduced efﬁciency—70% (H1), 50% (H2), and
30% (H3) [12,13]. Finally, replacement costs were
not applied because no replacement occurs for
absence below 20 consecutive days in this bank,
which did not happen in the study.
 
Results
 
This health economic study of the beneﬁts to the
employer of an inﬂuenza-vaccination program was
performed using staff of a Colombian bank which
at the time of the study had a total workforce of
2598 employees, 827 of whom volunteered to take
part in the study. Of these, 92% (759/827) com-
pleted the full follow-up period, 424 of whom were
vaccinated (56%) and 335 were not vaccinated
(44%). During the entire follow-up period ques-
tionnaire completion was always greater than 96%
in the vaccinated group and greater than 99% in the
nonvaccinated group.
The two groups were similar in terms of sex and
marital status (Table 2). Nevertheless, there were
signiﬁcant differences between the two groups. The
mean age of the nonvaccinated group was signiﬁ-
cantly lower than that of the vaccinated group
(
 
P
 
 
 
=
 
 0.001). This difference was unlikely to be of
clinical signiﬁcance and was only detectable because
of the large sample size increasing the sensitivity of
the 
 
ANOVA
 
 test. Vaccinated subjects tended to live in
more populous households (
 
P
 
 
 
<
 
 0.0001) with more
children than did the nonvaccinated group
(
 
P
 
 
 
<
 
 0.01) and their levels of education and work-
place responsibility tended to be lower than those of
the nonvaccinated group (
 
P
 
 
 
<
 
 0.001). These data
were conﬁrmed by multivariate analyses of the two
 
Table 2
 
Comparisons of  baseline information about the two study groups
 
Vaccinated Nonvaccinated
 
P
 
 value
Age, mean (
 
±
 
SD) 33.3 (
 
±
 
7.6) 31.7 (
 
±
 
6.0) 0.001
Sex, F/M 52%/48% 48%/52% NS
Marital status, married/single or divorced 54%/46% 50%/50% NS
Number of  people living in the household, mean (
 
± 
 
SD) 4.0 (
 
±
 
2.1) 3.4 (
 
±
 
1.2)
 
<
 
0.0001
Households with children 35% 23%
 
<
 
0.01
Highest education level
 
<
 
0.001
Secondary 14% 3%
University 72% 86%
Other 14% 11%
Main workplace responsibility
 
<
 
0.0001
Operations 55% 32%
Middle management 10% 11%
Support 29% 49%
Executive management 6% 8%
Smoking status
Currently 25% 25% NS
In past 14% 11%
Sick leaves in the past 6 months 29% 16% <0.0001
Chronic medical conditions
Any disease 14% 10% <0.05
Asthma 3.5% 4.1% NS
Bronchitis 3.08% 3.8% NS
Heart disease 2.38% 1.2% NS
Previous inﬂuenza vaccination in the past 74% 38% <0.0001
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groups (Table 3). Subjects in the vaccinated group
had taken signiﬁcantly more sick leave in the
6 months preceding the study than had the nonvac-
cinated group (
 
P
 
 
 
<
 
 0.0001) and were more likely to
have a chronic medical condition (
 
P
 
 
 
<
 
 0.05). Signif-
icantly more people choosing to be vaccinated in
this study had previously been vaccinated compared
to those choosing not to be vaccinated (
 
P
 
 
 
<
 
 0.0001).
At the start of the study all participants consid-
ered themselves to have good health. Overall, the
health status of the vaccinated group measured 8.8
(
 
±
 
 1.1) compared to 9.0 (
 
±
 
 0.6) in the nonvacci-
nated group. It is noteworthy that the vaccinated
group generally considered themselves to have
slightly but signiﬁcantly lower health status
(
 
P
 
 
 
<
 
 0.05) than the nonvaccinated group immedi-
ately before vaccination. Both the vaccinated [9.3
(
 
±
 
 0.8)] and nonvaccinated [9.1 (
 
±
 
 0.7)] groups con-
sidered themselves able to perform their usual activ-
ities without difﬁculty.
Postvaccination adverse events were recorded for
7 days after vaccination. Of the 424 vaccinated
employees, 2.6% (11/424) reported local or sys-
temic adverse events, the most frequent being sore
throat, fever, chills, cough, and muscle aches. Pain
was declared only three times.
 
ILI Frequency
 
In the following analyses the data for one vacci-
nated employee reporting an ILI episode were
excluded. This employee was absent for 26 days
and the illness was subsequently identiﬁed as
pneumonia.
One hundred and ninety-three subjects reported
a total of 221 ILI episodes. In the vaccinated group
a total of 63 episodes were reported by 61 people
and in the nonvaccinated group a total of 158 epi-
sodes were reported by 132 people. Overall, the
cumulative incidence of ILI was 14.6% in the vac-
cinated group and 39.4% in the nonvaccinated
group. Thus, vaccination signiﬁcantly reduced ILI
(
 
P
 
 
 
<
 
 0.0001). More unvaccinated subjects (20.45%,
27/132) than vaccinated subjects (3.27%, 2/61)
reported two or more ILI episodes (Table 4).
ILI attack rates were 15.09% in the vaccinated
group and 47.16% in the nonvaccinated group.
From these data, effectiveness rates for the vaccina-
tion program were 68.5% based on the attack rates
and 63% based on the cumulative incidence.
Information about ILI symptoms was available
for 216 of the 221 episodes. ILI symptoms were
generally comparable in the two groups although
fever, the most reported symptom, occurred less
often among the vaccinated group (85%) than
among the unvaccinated group (95%) (Table 5).
Figure 1 shows incidence of ILI episodes during
the 32-week follow-up period and demonstrates
four distinct periods:
1. Weeks 1 to 8: the number of ILI episodes was
similar between the two groups.
2. Weeks 8 to 13: there were approximately 10
times more ILI episodes in the nonvaccinated
group than in the vaccinated group.
3. Weeks 13 to 23: ILI was scarce.
4. Weeks 23 to 32: 89.8% (53/59) of reported ILI
occurred in the nonvaccinated group.
A similar pattern was observed for ILI-related
fever (data not shown).
 
Table 3
 
Multivariate analysis showed differences between the two groups
 
Vaccinated proﬁle Nonvaccinated proﬁle
Age 40–45 years 30–35 years
Responsibility level Operations or support responsibilities Support responsibilities
Salary level (SMLV) Less than 4 times SMLV 4–10 times SMLV
Education level Secondary University
 
SMLV, Annual Legal Minimum Salary Value decided by the National Government yearly. In 2002, SMLV 
 
=
 
 309.000 Colombian Pesos.
 
Table 4
 
Occurrence of  ILI episodes among vaccinated and
nonvaccinated groups
 
n
 
 ILI attacks
Vaccinated
 
n
 
 (%)
Nonvaccinated
 
n
 
 (%)
Total
 
N
 
 (%)
0 363 (85.6) 203 (60.6) 565 (74.4)
1 59 (13.9) 107 (31.9) 167 (22.0)
2 2 (0.5) 24 (7.2) 26 (3.4)
3 0 (0.0) 1 (0.3) 1 (0.1)
Total 424 (100) 335 (100) 759 (100)
 
Table 5
 
Distribution of  reported ILI symptoms
 
Symptoms
Vaccinated
 
n
 
 (%)
Nonvaccinated
 
n
 
 (%)
Total
 
N
 
 (%)
All ILI episodes 61 (100) 155 (100) 216 (100)
Fever 52 (85) 144 (95) 200 (93)
Chills 54 (88) 148 (95) 202 (94)
Muscle aches 59 (97) 151 (97) 210 (97)
Runny nose 59 (97) 151 (97) 210 (97)
Sore throat 59 (97) 151 (97) 210 (97)
Cough 59 (97) 139 (90) 198 (92)
Hoarse voice 59 (97) 136 (88) 195 (90)
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Because of the differences between the two study
groups shown in Table 2, logistic regression was
performed to adjust for factors—smoking status,
number of people in the household, presence of chil-
dren in the household, absenteeism during the past
6 months—that may have affected the risk of ILI
in either group. Chi-square (Cochran–Mantel–
Haenszel) tests were all signiﬁcant thereby proving
that reduced incidence of ILI among vaccinated
subjects is genuinely related to vaccination status
despite differences between other characteristics of
the two groups (data not shown).
 
Absenteeism/Sick Leave
 
During the study period 19 employees took sick
leave because of ILI, 10 vaccinated and 9 nonvac-
cinated. In total, 19 working days were lost among
vaccinated and 17 among nonvaccinated employ-
ees. Overall, the absence rate because of ILI symp-
toms was 2.59% in the vaccinated group and
2.69% in the nonvaccinated group.
A  total  of  327 days  were  occupied  with  ILI
and recovery in the vaccinated group (mean:
5.64 
 
±
 
 3.7 days per ILI episode) and 519 days in the
unvaccinated group (mean: 3.48 
 
±
 
 1.5 days per ILI
episode). The number of absentee employees who
were replaced during sick leave was negligible.
Presenteeism was calculated based on the total
number of days before each group felt better while
attending work—282 days in the vaccinated group
and 502 days in the nonvaccinated group. The
number of days used to calculate reduced produc-
tivity during presenteeism was obtained by sub-
tracting the total number of sick leave days from the
total number of days with ILI.
 
Economic Evaluation
 
The cost–beneﬁt evaluation, performed from the
company’s perspective, focused on direct business
costs—direct medical costs were not borne by the
company—and indirect beneﬁts of the inﬂuenza
vaccination program. Based on the ﬁnancial data
provided by the bank, the average individual daily
OI was US$387 per employee per day and the aver-
age daily salary was estimated to be US$58 per day.
The total cost of the vaccine program including the
cost of vaccines and administration costs—materi-
als and nurses hired to perform vaccination—was
US$2624 (i.e., US$6.2 per employee) and the total
cost of employees’ time away from work to receive
vaccination was estimated to be US$513 based on
salaries and US$3422 taking into account individ-
ual OI losses. The overall cost of postvaccination
adverse events was approximately US$3932 includ-
ing loss of productivity because of both absenteeism
and temporary inefﬁciency at work. In addition to
these costs, the effects of reduced productivity in
both vaccinated and unvaccinated groups because
of ILI was calculated based on three levels of pro-
ductivity—70% (H1), 50% (H2), and 30% (H3) of
normal. The results of these calculations are shown
in Tables 6 and 7. When labor costs alone are con-
sidered, vaccinating employees against inﬂuenza
saves US$6 to US$25 per vaccinated employee
(Table 6). Nevertheless, absent employees or
employees operating below their usual level of per-
formance will contribute less OI to the company
and when these income losses are considered vacci-
nation against inﬂuenza will save between US$89
and US$237 per vaccinated employee.
Sensitivity analyses were performed to determine
 
Figure 1
 
Occurrence of  ILI episodes during
the study period. The numbers of  ILI episodes
per week are shown for the nonvaccinated
(
 
n
 
 
 
=
 
 335) and vaccinated (
 
n
 
 
 
=
 
 423) groups and
for the whole study population. Clear reduc-
tions in the incidence of  ILI are seen between
weeks 8 and 13 and between weeks 23 and
32. Overall, most cases of  ILI occurred in the
nonvaccinated group.
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Table 6
 
Vaccination program costs and savings per
employee arising from vaccination—labor costs only
 
Total cost of  absenteeism, 
presenteeism and vaccination—labor 
costs only
H1* H2
 
†
 
H3
 
‡
 
Vaccinated (n = 424) 9604.53 12,882.50 16,160.47
Nonvaccinated (n = 335) 9740.91 15,576.16 21,411.41
Cost saving per employee 6.43  16.11  25.80
*H1: productivity rate with ILI symptoms = 70%.
†H2: productivity rate with ILI symptoms = 50%.
‡H3: productivity rate with ILI symptoms = 30%.
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the effects of vaccination coverage or levels of ILI in
the unvaccinated workforce on the CS (Fig. 2).
These sensitivity analyses were performed for each
of the three levels of productivity described above.
Depending on productivity, vaccination is cost
effective when 1 to 2 employees out of 10 are vac-
cinated, i.e., 10% to 20% coverage (Fig. 2a). Anal-
ysis of the sensitivity of savings to levels of ILI
showed that vaccination has ﬁnancial beneﬁts when
ILI rates among unvaccinated employees exceed
0.1, i.e., 10% (Fig. 2b).
Conclusions
The value of inﬂuenza vaccination in groups at risk
of severe complications from inﬂuenza infection,
the elderly and those with underlying chronic med-
ical conditions, is widely acknowledged and vacci-
nation also reduces morbidity caused by inﬂuenza
in healthy adults [4,6,7,14,17–21]. Nevertheless,
the economic beneﬁts of vaccination are generally
not recognized in areas of moderate inﬂuenza cir-
culation such as tropical regions. The present study
was performed to determine whether an employee
vaccination program is an attractive option for
employers seeking to reduce the ﬁnancial losses
associated with absenteeism and decreased work
productivity during the inﬂuenza season. The study
monitored rates of ILI and absenteeism in vacci-
nated and nonvaccinated people employed in a
Colombian bank.
ILI episodes had signiﬁcant impact on work pro-
ductivity even when the number of occasions of sick
leave remained low. ILI rates were lower in the vac-
cinated group (cumulative incidence of 14.6%) than
in the nonvaccinated group (cumulative incidence
of 39.4%). Nonvaccinated employees were three
times more likely than vaccinated employees to
experience at least one ILI episode. This study dem-
onstrates that an employee vaccination program is
effective—effectiveness rate of 68%—and safe.
Postvaccination adverse effects were reported by
just 2.6% of the vaccinated group, which is low
compared to published data (6.2% to 63.8%)
[4,6,19].  Nevertheless,  Wilde  et al.  [7]  reported
no absences resulting from vaccine-related adverse
events and apart from mild pain and swelling, no
signiﬁcant adverse events were related to the inﬂu-
enza vaccine. Therefore, although the low incidence
of vaccine-related adverse events could be due to
under-reporting by subjects this could be a genu-
inely low rate of adverse events.
This pragmatic observational study involved vol-
unteer subjects because a randomized, controlled
trial was inappropriate for an analysis of general
use of the vaccine. Nevertheless, statistical adjust-
ment to account for possible exposure factors was
essential to ensure that the two cohorts were statis-
tically comparable. The only factor associated with
different ILI rates between the two groups was vac-
cination status.
Table 7 Vaccination program costs and savings per
employee arising from vaccination—labor costs plus operating
income
Total cost of  absenteeism, presenteeism 
and  vaccination—labor costs plus 
operating income
H1* H2† H3‡
Vaccinated (n = 424) 56,656.22 81,787.50 106,918.78
Nonvaccinated (n = 335) 74,680.88 119,418.12 164,155.36
Cost saving per employee  89.30  163.58  237.85
*H1: productivity rate with ILI symptoms = 70%.
†H2: productivity rate with ILI symptoms = 50%.
‡H3: productivity rate with ILI symptoms = 30%.
Figure 2 Impact of  vaccination coverage rate (a) or rate of  ILI among
nonvaccinated employees (b) on annual total cost-savings. Total sav-
ings resulting from an employee vaccination program were calculated
based on (a) vaccination coverage (up to 9 out of  10 employees vac-
cinated) or (b) ILI occurring in up to 6 out of  10 nonvaccinated
employees. These calculations were performed taking into account
the reduced productivity resulting from people being at work when ill.
Three productivity rates were considered: 70% (H1), 50% (H2), and
30% (H3) of  normal.
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In this study, very low absenteeism rates were
reported. Only one case of long-term sick leave—
26 days—was reported and this individual was sub-
sequently conﬁrmed to be suffering from pneumo-
nia. Also, the bank operated a “no replacement
policy” for sick leave of less than 20 days duration.
The probable effect of this policy would be to
underestimate the impact of ILI among sick employ-
ees who continued working—so-called presentee-
ism. Also, the presence of sick colleagues in the
workplace would increase levels of ILI contagious-
ness and increase ILI attack rates in the study
population. Despite these circumstances, the vacci-
nation demonstrated a high level of effectiveness
(68%).
The inﬂuenza season in South America is differ-
ent from that in North America so different strains
of inﬂuenza virus might be involved in these geo-
graphically distinct regions and most effective
vaccination might require vaccines with different
viral strains [17]. Nevertheless, Brazilian Grupo
Regional de Obseração da Grippe (GROG) and
unpublished epidemiological surveys of the São
Paulo city area report epidemiological data similar
to the results of surveys performed in North Amer-
ica and Europe. Therefore, Burckel et al. considered
it reasonable to apply data from the Americas to
Brazil [17]. The results of the current study can also
be assumed to be similar to those reported in North
America and Europe.
When all study conditions are considered (sam-
ple size, inﬂuenza circulation, matching of circulat-
ing inﬂuenza strains, and the ones contained in the
vaccine) and assumptions made concerning reduced
productivity rates, the CS per vaccinated employee
in this study varied between US$89 (70% efﬁciency)
and US$237 (30% efﬁciency) when both labor costs
and OI are considered. Even when OI is excluded
from the analysis, savings of up to US$25 per
employee are made in addition to the health beneﬁts
of vaccination. Clearly, the total amount saved by
the company will be greater if more employees are
vaccinated and the more ILI that is prevented, as
demonstrated by the sensitivity analyses shown in
Figure 2. These ﬁgures were calculated using a
mean salary for each employee, rather than using
actual salaries. Although it is expected that actual
salaries might affect the amount saved [16] we agree
with Postma et al. [11] that using different salary
levels might lead to ethically unacceptable behavior
such as only vaccinating those employees earning a
salary that leads to CS.
The results of this study demonstrate the poten-
tially signiﬁcant economic beneﬁts of the employee
vaccination program especially when the study
conditions are taken into account—not all bank
employees were involved in the study, there was
only a mild outbreak of inﬂuenza during the study
period, optimistic hypotheses of lost productivity
were considered; effectiveness at work could be
considered much lower when ill. Additionally, the
sensitivity analysis showed that possible expansion
of inﬂuenza vaccination to most of the company
would lead to substantial cost savings for the
employer, even with conservative assumptions.
Knowing the impact that vaccination coverage rate
has on the return on investment, substantial effort
should be made to communicate and persuade
employees to be vaccinated to maximize both the
health and ﬁnancial beneﬁts of the program.
This study was supported by a grant from Aventis Pasteur.
Publication of the ﬁndings was not contingent on the
Sponsor’s approval of the article.
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